Analysistl1aimmunologytevaclinical trials
Teva Advances Duvakitug Toward Phase-3 Clinical Trials
|
3.9
Kontra Investments' Feb 3, 2026 Substack outlines a bullish thesis on Teva Pharmaceutical Industries (NYSE:TEVA), reporting shares at $33.07 on Jan. 28 and trailing and forward P/Es of 27.45 and 11.70. It highlights Duvakitug (TEV-’574)'s Phase 2b success in ulcerative colitis and Crohn's, its anti-TL1a anti-fibrosis mechanism, and Kontra's view that Phase 3 entry and new indications could materially re-rate Teva's valuation.
Scoring Rationale
Company-specific Phase 2 clinical progress increases interest, but reliance on a single analyst thesis and limited AI/ML relevance lower impact.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
